<DOC>
	<DOCNO>NCT02719171</DOCNO>
	<brief_summary>The overall purpose trial ass clinical efficacy safety different subcutaneous dos BI 655066/ABBV-066/risankizumab adult patient psoriatic arthritis order select dose clinical trial .</brief_summary>
	<brief_title>BI 655066/ABBV-066/Risankizumab Compared Placebo Patients With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Inclusion criterion : Have psoriatic arthritis ( PsA ) symptoms &gt; /= 6 month prior screen , assess investigator Have PsA basis Classification Criteria Psoriatic Arthritis ( CASPAR ) peripheral symptom screen visit , assess investigator Have &gt; /= 5 tender joint &gt; /= 5 swollen joint screen randomisation visit , assess investigator At least one psoriasis ( PsO ) lesion document personal history PsO screening , assess investigator If patient receive concurrent PsA treatment , need stable dos Active PsA inadequately control standard dos nonsteroidal antiinflammatory drug ( NSAIDs ) administer &gt; /= 4 week , traditional diseasemodifying antirheumatic drug ( DMARDs ) ( include sulfasalazine ) administer &gt; /= 3 month , tumor necrosis factor inhibitor ( TNFi ) agent , subject intolerant NSAIDs DMARDs TNFi agent , assess investigator Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : Major chronic inflammatory connective tissue disease PsA ( e.g . rheumatoid arthritis , systemic lupus erythematosus , ankylose spondylitis , Lyme disease , gout ) fibromyalgia , assess investigator Has receive therapeutic agent directly target IL12/23 ( include ustekinumab ) , IL23 IL17 ( include secukinumab ) Prior use two different TNFi agent Use follow treatment : TNFi agent within 12 week , etanercept within 8 week , leflunomide without cholestyramine washout within 8 week , systemic nonbiologic medication psoriatic arthritis psoriasis photochemotherapy within 4 week , intraarticular injection ( include steroid ) intramuscular intravenous corticosteroid treatment within 4 week , topical psoriasis medication phototherapy within 2 week , low high potency opioid analgesic within 2 week prior randomisation Plans administration live vaccine study period within 6 week prior randomisation History allergy/hypersensitivity systemically administer biologic agent excipients Active systemic infection last 2 week ( exception : common cold ) prior randomisation , assess investigator Chronic relevant acute infection include HIV , viral hepatitis ( ) active tuberculosis . Patients positive QuantiFERON TB purify protein derivate ( PPD ) test may participate study work ( accord local practice/guidelines ) establish conclusively patient evidence active tuberculosis . Any document active suspected malignancy history malignancy within 5 year prior screen , except appropriately treat basal squamous cell carcinoma skin situ carcinoma uterine cervix Major surgery perform within 12 week prior randomisation plan within 32 week randomisation ( e.g . hip replacement , aneurysm removal , stomach ligation ) , assess investigator Total white blood count ( WBC ) &lt; 3,000/µL , platelet &lt; 100,000/µL neutrophil &lt; 1,500/µL , hemoglobin &lt; 8.5 g/dL screen Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2x upper limit normal , serum direct bilirubin &gt; /= 1.5 mg/dL screen Positive rheumatoid factor anticycliccitrullinated peptide ( antiCCP ) antibodies screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>